Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PER2 | O15055 | 16/20 | 0.39 |
| ▸ | CRY1 | Q16526 | 16/20 | 0.39 |
| ▸ | CRY2 | Q49AN0 | 16/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTR4 | Q13639 | 4/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3035583 | 1.00 | PER2 (0.39) | PER2CRY1CRY2ALDH1A1HTR4 | |
| SCHEMBL4669731 | 1.00 | PER2 (0.39) | PER2CRY1CRY2ALDH1A1HTR4 | |
| SCHEMBL2918659 | 1.00 | PER2 (0.39) | PER2CRY1CRY2ALDH1A1HTR4 | |
| SCHEMBL2909266 | 1.00 | PER2 (0.39) | PER2CRY1CRY2ALDH1A1HTR4 | |
| SCHEMBL3040095 | 1.00 | PER2 (0.39) | PER2CRY1CRY2ALDH1A1HTR4 | |
| Hydrochloric Acid SCHEMBL2912478 | 0.99 | PER2 (0.38) | PER2CRY1CRY2ALDH1A1HTR4 | |
| SCHEMBL3043624 | 0.88 | PER2 (0.42) | PER2CRY1CRY2 | |
| SCHEMBL3792794 | 0.88 | PER2 (0.42) | PER2CRY1CRY2 | |
| SCHEMBL3045274 | 0.87 | — | — | |
| SCHEMBL1073407 | 0.86 | HTR4 (0.34) | HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11642339-B2 | Methods of treating symptoms of gastroparesis using velusetrag | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-05-09 | — | — | US | claimed |
| US-20190030022-A1 | METHODS OF TREATING SYMPTOMS OF GASTROPARESIS USING VELUSETRAG | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-01-31 | — | — | US | claimed |
| EP-2419104-B1 | COMBINATIONS OF 5-HT4 RECEPTOR AGONISTS AND ACETYLCHOLINESTERASE INHIBITORS FOR TREATMENT OF COGNITIVE DISORDERS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2017-11-08 | — | — | EP | claimed |
| US-9402840-B2 | Crystalline form of a quinolinone-carboxamide compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-08-02 | — | — | US | claimed |
| US-20160095849-A1 | CRYSTALLINE FORM OF A QUINOLINONE-CARBOXAMIDE COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-04-07 | — | — | US | claimed |
| US-9126994-B2 | Crystalline form of a quinolinone-carboxamide compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-09-08 | — | — | US | claimed |
| US-20140256769-A1 | CRYSTALLINE FORM OF A QUINOLINONE-CARBOXAMIDE COMPOUND | THERAVANCE, INC. (US) | 2014-09-11 | — | — | US | claimed |
| US-20140057939-A1 | 5-HT4 RECEPTOR AGONIST COMPOUNDS FOR TREATMENT OF COGNITIVE DISORDERS | THERAVANCE, INC. (US) | 2014-02-27 | — | — | US | claimed |
| US-8658671-B2 | Crystalline form of a quinolinone-carboxamide compound | THERAVANCE, INC. (US) | 2014-02-25 | — | — | US | claimed |
| US-8404711-B2 | 5-HT4 receptor agonist compounds for treatment of cognitive disorders | THERAVANCE, INC. (US) | 2013-03-26 | — | — | US | claimed |
| US-7763637-B2 | Quinolinone-carboxamide compounds as 5-HT4, receptor agonists | THERAVANCE, INC. (US) | 2010-07-27 | — | — | US | claimed |
| US-7728004-B2 | crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide or solvate thereof; treating disease associated with 5-HT4 receptor activity; gastrointestinal tract disorder | THERAVANCE, INC. (US) | 2010-06-01 | — | — | US | claimed |
| EP-1735304-B1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE INC (US) | 2009-01-07 | — | — | EP | claimed |
| US-20080287486-A1 | Prokinetic agent for bowel preparation | THERAVANCE, INC. | 2008-11-20 | — | — | US | claimed |
| US-20080176895-A1 | Quinolinone-carboxamide compounds as 5-HT4, receptor agonists | ALFASIGMA S.P.A. (IT) | 2008-07-24 | — | — | US | claimed |
| US-7375114-B2 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2008-05-20 | — | — | US | claimed |
| EP-1735304-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | Theravance, Inc. (US) | 2006-12-27 | — | — | EP | claimed |
| US-20060229332-A1 | crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide or solvate thereof; treating disease associated with 5-HT4 receptor activity; gastrointestinal tract disorder | THERAVANCE, INC. | 2006-10-12 | — | — | US | claimed |
| WO-2005100350-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2005-10-27 | — | — | WO | claimed |
| US-20050228014-A1 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. | 2005-10-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228014-A1 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | HTR4, HTR5A, HTR1A | PER2 2844/4885CRY1 3312/4885CRY2 2733/4885 |
| US-20080287486-A1 | Prokinetic agent for bowel preparation | PROKR1, PROKR2, MLNR | PER2 3093/4885CRY1 4535/4885CRY2 4355/4885 |
| US-20140256769-A1 | CRYSTALLINE FORM OF A QUINOLINONE-CARBOXAMIDE COMPOUND | HTR5A, HTR4, HTR2C | PER2 3469/4885CRY1 2791/4885CRY2 2695/4885 |
| US-20160095849-A1 | CRYSTALLINE FORM OF A QUINOLINONE-CARBOXAMIDE COMPOUND | HTR5A, HTR4, HTR2C | PER2 3469/4885CRY1 2791/4885CRY2 2695/4885 |
| US-20080176895-A1 | Quinolinone-carboxamide compounds as 5-HT4, receptor agonists | HTR4, HTR5A, HTR1A | PER2 2581/4885CRY1 2927/4885CRY2 2451/4885 |
| US-11642339-B2 | Methods of treating symptoms of gastroparesis using velusetrag | SLC10A2, GIPR, VIPR2 | PER2 1954/4885CRY1 3390/4885CRY2 2884/4885 |
| US-20060229332-A1 | crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide or solvate thereof; treating disease associated with 5-HT4 receptor activity; gastrointestinal tract disorder | HTR4, HTR5A, HTR2C | PER2 3039/4885CRY1 3340/4885CRY2 3482/4885 |
| US-20190030022-A1 | METHODS OF TREATING SYMPTOMS OF GASTROPARESIS USING VELUSETRAG | SLC10A2, GIPR, VIPR2 | PER2 1954/4885CRY1 3390/4885CRY2 2884/4885 |
| US-20140057939-A1 | 5-HT4 RECEPTOR AGONIST COMPOUNDS FOR TREATMENT OF COGNITIVE DISORDERS | HTR4, HTR5A, HTR3B | PER2 3473/4885CRY1 4338/4885CRY2 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.